Suchergebnisse - "Chen, Jianhua"

PubPharm (17)

1

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Tang, K. | Cho, B. | +126

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF9. - PMID 37878779

2

Interim survival analysis of the randomized phase III GEMSTONE-302 trial : sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

enthalten in: Nature cancer | 2023

von Zhou, C. | Wang, Z. | Sun, M. | +31

ErratumIn: Nat Cancer. 2024 Jan 5;:. - PMID 38182915

3

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC : Extended Follow-Up of CameL Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Zhou, C. | Chen, G. | Huang, Y. | +54

4

Validation of different personalized risk models of chemotherapy-induced nausea and vomiting : results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin

enthalten in: Cancer communications (London, England) | 2023

von Zhao, Y. | Zhao, B. | Chen, G. | +15

5

AENEAS : A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Lu, S. | Dong, X. | Jian, H. | +56

CommentIn: J Clin Oncol. 2022 Sep 20;40(27):3103-3105. - PMID 35679530

6

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302) : A Randomized Phase III Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Shen, L. | Kato, K. | Kim, S. | +28

ErratumIn: J Clin Oncol. 2023 Dec 19;:JCO2302629. - PMID 38113437

7

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq) : A Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Ren, S. | Chen, J. | Xu, X. | +31

CommentIn: J Thorac Oncol. 2022 Apr;17(4):477-480. - PMID 35307102

8

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302) : interim and final analyses of a double-blind, randomised, phase 3 clinical trial

enthalten in: The Lancet. Oncology | 2022

von Zhou, C. | Wang, Z. | Sun, Y. | +17

CommentIn: Lancet Oncol. 2022 Feb;23(2):186-188. - PMID 35038431

9

Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer : A double-blind, randomized, placebo-controlled study

enthalten in: Frontiers in immunology | 2022

von Dong, X. | Huang, Y. | Yi, T. | +14

10

Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation : A single-center randomized controlled study

enthalten in: Clinical cardiology | 2021

von Wang, W. | Chen, Q. | Zhang, F. | +6